Jules A. A. C. Heuberger

<scp>LRRK2</scp> Inhibition by <scp>BIIB122</scp> in Healthy Participants and Patients with Parkinson's Disease

Danna Jennings, Sarah Huntwork‐Rodriguez, Maurits F. J. M. Vissers et al. · Movement Disorders · 2023 · 97 citations · Full text

Safety, pharmacokinetics and target engagement of novel <scp>RIPK1</scp> inhibitor <scp>SAR443060</scp> (<scp>DNL747</scp>) for neurodegenerative disorders: Randomized, <scp>placebo‐controlled</scp>, <scp>double‐blind</scp> phase I/Ib studies in healthy subjects and patients

Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld et al. · Clinical and Translational Science · 2022 · 84 citations · Full text

When is Protein Binding Important?*

Jules A. A. C. Heuberger, Stephan Schmidt, Hartmut Derendorf · Journal of Pharmaceutical Sciences · 2013 · 79 citations · Full text

Protein Chemistry, Protein Function, Protein Assembly +5

Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis

Guido van Amerongen, Kawita M. S. Kanhai, Anne Catrien Baakman et al. · Clinical Therapeutics · 2017 · 78 citations · Full text

Cannabis Use, Pain Disorders, Neurological Assessment +14

Population Pharmacokinetic Model of THC Integrates Oral, Intravenous, and Pulmonary Dosing and Characterizes Short- and Long-term Pharmacokinetics

Jules A. A. C. Heuberger, Zheng Guan, Olubukayo‐Opeyemi Oyetayo et al. · Clinical Pharmacokinetics · 2014 · 75 citations

Population Pharmacokinetic Model, Pharmacokinetic Modeling, Thc Integrates Oral +7